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Abstract
Background: Large myocardial infarction (MI) is associated with adverse left ventricular (LV) remodeling (LVR). We
studied the nature of LVR, with specific attention to non-transmural MIs, and the association of peak CK-MB with
recovery and chronic phase scar size and LVR.
Methods: Altogether 41 patients underwent prospectively repeated cardiovascular magnetic resonance at a
median of 22 (interquartile range 9–29) days and 10 (8–16) months after the first revascularized MI. Transmural MI
was defined as ≥75% enhancement in at least one myocardial segment.
Results: Peak CK-MB was 86 (40–216) μg/L in median, while recovery and chronic phase scar size were 13 (3–23) %
and 8 (2–19) %. Altogether 33 patients (81%) had a non-transmural MI. Peak CK-MB had a strong correlation with
recovery and chronic scar size (r ≥ 0.80 for all, r ≥ 0.74 for non-transmural MIs; p < 0.001). Peak CK-MB, recovery scar
size, and chronic scar size, were all strongly correlated with chronic wall motion abnormality index (WMAi) (r ≥ 0.75
for all, r ≥ 0.73 for non-transmural MIs; p < 0.001). There was proportional scar size and LV mass resorption of 26%
(0–50%) and 6% (− 2–14%) in median. Young age (< 60 years, median) was associated with greater LV mass
resorption (median 9%vs.1%, p = 0.007).
Conclusions: Peak CK-MB has a strong association with chronic scar size and wall motion abnormalities after
revascularized non-transmural MI. Considerable infarct resorption happens after the first-month recovery phase. LV
mass resorption is related to age, being more common in younger patients.
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Background
Left ventricular (LV) remodeling after acute myocardial in-
farction (MI) is a major precursor of heart failure [1, 2] and
predictor of mortality [3]. Remodeling occurs despite
successful reperfusion and sustained patency of the infarct-
related artery [4]. Early remodeling during first weeks after
MI involves infarct expansion and scar formation, while late
remodeling involves adaptive changes in the non-infarcted
myocardium, such as myocyte hypertrophy, chamber dilata-
tion or interstitial fibrosis, to balance increased loading con-
ditions [5, 6].
The best predictor of LV dysfunction after MI is the
infarct size [2, 7]. Most past studies have focused on
large MIs and subsequent global LV remodeling, and it
has been presented that remodeling rarely occurs with
infarct size less than 18.5% of LV volume [8]. However,
due to improved revascularization therapy, chronic in-
farct size tends to be smaller. The course of LV remodel-
ing after smaller non-transmural MIs is less well
established and there is still a lack of prospective studies
with repeated comprehensive cardiovascular magnetic
resonance (CMR) imaging. CMR provides high fidelity
and normalized information of the LV anatomy, global
and local function, and tissue injury after MI [9], which
enables also the detection of subtle changes. The
preferred biomarkers of cardiac necrosis after MI are
troponins due to high clinical sensitivity and myocardial
tissue specificity, and CK-MB is the best alternative [10].
Troponins and CK-MB have all showed good correlation
with infarct size and global ejection fraction after large
reperfused MI, although the relation between bio-
markers and infarct size might be less robust in smaller
infarcts [11].
The purpose of this study was therefore, using re-
peated CMR imaging, to study 1) the course of LV
remodeling after the first revascularized spontaneous
acute MI, 2) the more subtle remodeling process after
non-transmural MI, and 3) the association of peak
CK-MB with recovery phase (1–4 weeks) and chronic
phase (> 6 months) scar size, and global and local LV
dysfunction. We also made a post-hoc analysis of long-
term survival.
Methods
Patients and study design
This is a CMR substudy of the prospectively conducted
ISKE project (Imaging acute myocardial ischemia by
body surface potential mapping) [12]. In brief, from June
2003 to June 2005, patients admitted to the Coronary
Care Unit of Helsinki University Hospital for suspected
acute coronary syndrome were screened during office hours.
Inclusion criteria were prolonged chest pain ≥20 min within
48 h of recruitment, associated with evidence of acute ische-
mia in the initial 12-lead electrocardiogram (ST-segment
elevation, −depression, or T-wave inversion in ≥2 contiguous
leads), or elevated cardiac enzymes (CK-MB mass > 7 μg/L
or troponin T > 0.03 μg/L), or both [12]. Patients with bun-
dle branch block, atrial fibrillation, pacemaker, or need for
ventilator support, were excluded. Also patients with contra-
indications for CMR, such as pacemakers, defibrillators or
claustrophobia, were excluded.
In this CMR substudy, all eligible patients were di-
agnosed with acute spontaneous type 1 MI [10], with
elevated cardiac enzymes or scar at CMR, and
underwent revascularization in the acute phase. Both
patients with ST-elevation MI (STEMI) and non-ST
elevation MI (NSTEMI) at presentation were included.
All patients with prior MI, percutaneous coronary inter-
vention (PCI), or coronary artery bypass craft (CABG),
were excluded.
All patients were treated with successful PCI, CABG
or thrombolysis in less than 3 days after the admission
except for one patient treated successfully with CABG
after 9 days during the same hospital stay, and received
optimal secondary preventive medication for coronary
artery disease.
All patients underwent two CMR examinations after
MI to assess LV and infarct remodeling. The first CMR
study occurred during the recovery phase 7–30 days
after MI, and the second at the chronic infarct phase
≥6 months after MI. Revascularization was always per-
formed before the first CMR.
CK-MB was measured according to routine clinical
praxis: at arrival at the hospital, the following even-
ing or morning, or both. The maximum value of
these measurements, peak CK-MB, served as a meas-
ure of infarct size. In most patients, measurement of
peak CK-MB occurred 12–24 h after the onset of
chest pain.
CMR methods
CMR imaging was performed with a 1.5-T imager (Sonata,
Siemens Medical Solutions) using body-array coil as a
receiver. Breath-hold cine CMR was performed using
retrospectively electrocardiographically gated segmented
imaging with steady-state free-precession (SSFP). Cine
CMR images were acquired in vertical, horizontal long-
axis and short-axis planes covering the whole LV. Typical
imaging parameters were TR/TE 3.0/1.51 ms, flip angle 52
degrees, 256 × 256 matrix and 240 × 340 mm field of view.
Slice thickness was 6 mm. The temporal resolution was
42–47 ms.
Ten to fifteen minutes after intravenous injection of a
contrast agent (gadodiamide, Omniscan TM, GE Health-
care, 0.2 mmol/kg), late gadolinium enhancement (LGE)
images were acquired in the same views as for cine im-
ages, using inversion-recovery turbo fast-low angle shot
(FLASH). Typical imaging parameters were TR/TE 8.6/
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4.3 ms, 256 × 256 matrix, slice thickness 8 mm and inter-
slice gap 20%. Inversion times were optimized to null the
signal intensity of normal myocardium (250–300 ms).
CMR analysis
CMR images were analyzed by two experienced observers
blinded to clinical outcome. LV mass, end-diastolic
(EDV) and end-systolic (ESV) volumes were evalu-
ated by manually tracing the epicardial border (ex-
cluding epicardial fat) and endocardial borders
(excluding papillary muscles) at end-diastole and
-systole for short-axis slices. Volumetric indices were
obtained by dividing values by body surface area.
LGE images were analyzed using the standard 17-
segment model of the LV, leaving out the apex [13].
Scar area was manually delineated, the method of
which has recently shown the lowest overall variabil-
ity for quantification of MI when analyzed by experi-
enced observers [14]. The global scar size was
calculated by dividing the sum of segmental scar
areas by the total area of all segments. Infarct trans-
murality was evaluated as the percentage area in each
segment. Transmural MI was defined as ≥75% en-
hancement in at least one myocardial segment on re-
covery phase CMR [15], irrespectively of STEMI/
NSTEMI classification at presentation.
Repeatability of LGE analyses was also studied: 384
segments were analyzed for the presence of scar by two
independent observers, and results were concordant for
366 (95%) of the segments (kappa = 0.86).
Segmental wall motion was visually estimated, blinded
to LGE results. The degree of wall motion abnormality
in each segment was scored as 0 (normokinesia), 1
(hypokinesia), 2 (akinesia) or 3 (dyskinesia). Wall motion
abnormality index (WMAi) of the LV was then calcu-
lated as the sum of all segmental scores.
Follow-up
Follow-up data of major adverse cardiac events (MACEs)
was post-hoc collected until the end of year 2012
based on local and national registries, including uni-
versity and local hospital records, general practi-
tioners’ records and the mortality information from
the public organization Statistics Finland, without
direct contact to patients. The survival time was cal-
culated from the first CMR and only one event was
tabulated per subject. A MACE was defined as car-
diovascular death, aborted sudden death, heart fail-
ure hospitalization, or recurrent MI. Aborted sudden
death was defined as documented resuscitation from
cardiac arrest or appropriate implantable cardioverter
defibrillator therapy, i.e. antitachycardia pacing or
shock, for ventricular tachycardia or fibrillation.
Statistical analysis
Continuous variables are presented as median (inter-
quartile range [IQR]) and categorical variables as
frequency (%). Comparison between continuous vari-
ables was performed with Mann-Whitney U test. CMR
variables were compared between recovery and chronic
phase studies using related samples Wilcoxon signed
rank test. Correlation between variables was calculated
using Spearman’s method. Linear regression was
performed to identify predictors of chronic phase ejec-
tion fraction (EF), reaching sufficient normality of resid-
uals. In survival analysis, Cox regression analysis was
performed to identify predictors of MACEs. A p-value of
< 0.05 was considered statistically significant and all tests
were 2-sided. Statistical analysis was performed on SPSS
21 statistical package (SPSS, Chigaco, IL).
Results
Study group and baseline data
From June 2003 to June 2005, altogether 85 patients
were enrolled as a part of the ISKE project. Deriv-
ation of the CMR study group of 41 patients with
their first revascularized MI and complete CMRs data
are presented in Fig. 1A. Patients presented with a
median peak CK-MB of 86 μg/L (range 5–736 μg/L,
IQR 40–216 μg/L) (Table 1). Half (47%) of the pa-
tients had a multiple vessel disease and 59% anterior
infarct. Thirty-five (85%) patients were treated with
PCI, four (10%) with CABG and 2 (5%) with thromb-
olysis only.
Recovery phase CMR study
Recovery phase CMR study was performed in a median of
22 (9–29) days after hospital admission. Median scar size
was 13% (range 0–42%, IQR 3–23%) of the LV (Table 2).
Six (15%) patients with minor infarcts (peak CK-MB range
19–39 μg/L) had no visible scar at CMR, while two patients
with small scars (2 and 5%) had normal peak CK-MB (5
and 7 μg/L). Altogether 33 patients (81%) had a non-
transmural MI with a median peak CK-MB of 66 (30–146)
μg/L, while eight had a transmural MI with a median peak
CK-MB of 261 (209–557) μg/L.
In the whole study group (n = 41), peak CK-MB had a
strong correlation with recovery phase scar size (r = 0.80,
p < 0.001) (Fig. 1B), moderate correlation with ESV, EF
and WMAi, weak correlation with EDV, and showed a
trend with LV mass (r = 0.285, p = 0.071) (Table 3).
There were similar correlations in the subgroup of non-
transmural MIs.
Chronic phase CMR study
Chronic phase CMR study was performed in a median
of 10 (8–16) months after hospital admission.
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Fig. 1 Study flow chart (a). Correlation of peak CK-MB with recovery (b) and chronic (c) scar size at CMR (n = 41). Correlation of recovery scar size
with scar size change between CMRs (d); only patients with visible scar (n = 35) included. Correlation of age with left ventricular (LV) mass change
between CMRs (e) (n = 41). Abbreviations: CMR cardiovascular magnetic resonance, MI myocardial infarction, UAP unstable angina pectoris, MACE
major adverse cardiac event
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Peak CK-MB had a strong correlation with chronic
scar size (r = 0.83, p < 0.001) (Fig. 1C) and chronic
WMAi (r = 0.75, p < 0.001) (Table 3), moderate correl-
ation with chronic ESV and EF, and showed a trend with
EDV, but not with chronic LV mass (r = 0.22, p = 0.175).
Similar, but weaker correlations with ESV and EF, were
found in non-transmural MI group.
Also, both recovery and chronic phase scar size had a
strong correlation with chronic WMAi (r ≥ 0.80, p < 0.001
for both) (Fig. 2), and similar strong correlations were
found in non-transmural MI group.
Late remodeling
Between CMRs, there were no changes in median volumes
or EFs, but there was a significant reduction in median scar
size (13 vs. 8%, p = 0.001), LV mass (78 g/m2 vs. 72 g/m2,
p = 0.001), and WMAi (6 vs. 5, p < 0.001) (Table 2).
Peak CK-MB or recovery scar size were not associ-
ated with late remodeling, i.e. change in LV mass or
WMAi between CMRs. Considering the association of
all continuous baseline and recovery phase CMR vari-
ables with late remodeling parameters, the only sig-
nificant correlation was found between age and LV
mass change (r = 0.47, p = 0.002), meaning that youn-
ger age was associated with greater LV mass resorp-
tion (Fig. 1E). The proportional LV mass resorption
was 6% in median (from 2% increase to 14% reduc-
tion), while younger half of the patients (< 60 years)
experienced median LV mass resorption of 9% (6–
17%) vs. 1% (1% increase to 10% resorption) in older
ones (p = 0.007).
In 35 patients with visible scar at CMR, the median
absolute and proportional scar size resorption be-
tween CMRs were 3% (0–8%) and 26% (0–50%).
Absolute scar change correlated with recovery phase scar
size (r = − 0.59, p < 0.001) (Fig. 1D), i.e. large MIs had
greater absolute scar resorption. However, proportional
scar resorption was not associated with scar size.
Predictors of chronic EF
Univariate predictors of chronic EF included peak CK-
MB, recovery phase scar size, EDV, ESV, EF, LV mass
and WMAi. By multivariate regression (stepwise for-
ward), the significant predictors of chronic phase EF
were recovery EF (Beta = 0.595, p < 0.001) and peak CK-
MB (Beta = − 0.312, p = 0.012).
Long-term survival
Nine (21%) patients reached a MACE during a me-
dian follow-up of 7.7 (4.1–8.5) years. There were one
cardiovascular death, one aborted sudden death, two
Table 1 Baseline characteristics (n = 41)
Demographics
Age, year 60 (50–67)
Gender, male 34 (83)
Body mass index, kg/m2 27 (24–30)
Cardiovascular risk factors
Dyslipidemia 35 (85)
Hypertension 14 (34)
Diabetes 8 (20)
Smoking 16 (39)
Family risk for coronary artery disease 25 (61)
ST-elevation myocardial infarction 33 (81)
Culprit coronary artery
Left anterior descending (or left main) 24 (59)
Circumflex artery 5 (12)
Right coronary 12 (29)
Multiple vessel disease 19 (46)
Anterior infarct 24 (59)
Method of reperfusion
Thrombolysis 2 (5)
Primary percutaneus coronary intervention 35 (85)
Coronary artery bypass graft 4 (10)
Peak CK-MB (μg/L) 86 (40–216)
Discharge medication
Aspirin 38 (93)
Clopidogrel 37 (90)
Beta blocker 40 (98)
ACE-inhibitor/AT2-blocker 26 (63)
Statin 40 (98)
Diuretic 3 (7)
Nitrate 1 (2)
Warfarin 2 (5)
Values are median (interquartile range) or n (%)
Table 2 Left ventricular remodeling: comparison of CMR indices
(n = 41)
Recovery phase Chronic phase p-value
LV end-diastolic
volume, ml/m2
79 (61–90) 70 (65–82) 0.115
LV end-systolic
volume, ml/m2
39 (28–48) 36 (28–43) 0.197
Stroke volume,
ml/m2
38 (33–44) 37 (31–42) 0.138
LV ejection
fraction, %
52 (45–57) 51 (45–56) 0.791
LV mass, g/m2 78 (69–84) 72 (61–82) 0.001
WMAi, score 6 (3–12) 5 (1–9) < 0.001
Scar size, % of LV 13 (3–23) 8 (2–19) 0.001
Values are median (interquartile range)
Abbreviations: CMR cardiovascular magnetic resonance, LV left ventricular.
WMAi Wall motion abnormality index
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heart failure hospitalizations and five recurrent MIs.
In univariate Cox regression analysis of all baseline,
recovery and chronic phase CMR indices, and late remod-
elling variables, the only significant predictor of MACEs
was WMAi at chronic phase (hazard ratio [HR] 1.15, 95%
confidence interval [CI] 1.01–1.31, p = 0.038). Multiple
vessel disease (HR 4.6, 95% CI 0.9–22.3, p = 0.060), EDV
late remodelling (HR = 1.04, 95% CI 1.00–1.08, p = 0.051)
and WMAi late remodeling (HR = 1.23, 95% CI 0.98–1.55,
p = 0.068) showed a trend in predicting MACEs.
Discussion
Main findings
The main finding of this study is that peak CK-MB has a
strong association with chronic scar size and WMAi
after revascularized MI, with similar correlations in
patients with non-transmural MIs only. Peak CK-MB
predicted also chronic EF, independently of recovery
phase EF. After the first weeks recovery phase, there still
happens considerable proportional infarct resorption of
one quarter in median, independently of infarct size, and
Table 3 Correlation between peak CK-MB and scar size, left ventricular volumes, ejection fraction (EF) and wall motion abnormality
index (WMAi) at recovery and chronic phase after myocardial infarction
Recovery phase CMR
(correlation to peak CK-MB)
Chronic phase CMR
(correlation to peak CK-MB)
All (n = 41) Non-transmural MI (n = 33) All (n = 41) Non-transmural MI (n = 33)
Scar size, % 0.80 (p < 0.001) 0.74 (p < 0.001) 0.83 (p < 0.001) 0.78 (p < 0.001)
EDV, ml/m2 0.49 (p = 0.001) 0.47 (p = 0.006) 0.31 (p = 0.050) 0.317 (p = 0.072)
ESV, ml/m2 0.66 (p < 0.001) 0.56 (p = 0.001) 0.53 (p < 0.001) 0.42 (p = 0.015)
EF, % −0.64 (p < 0.001) −0.52 (p = 0.002) −0.62 (p < 0.001) 0.45 (p = 0.008)
WMAi, score 0.69 (p < 0.001) 0.60 (p < 0.001) 0.75 (p < 0.001) 0.73 (p < 0.001)
Values are Spearman correlation coefficients (p-value)
Abbreviations: CMR cardiovascular magnetic resonance, EDV end-diastolic volume, EF ejection fraction, ESV end-systolic volume, WMAi wall motion
abnormality index
Fig. 2 Correlation of peak CK-MB (a, b), recovery scar size (c, d) and chronic scar size (e, f) with chronic ejection fraction (EF) and wall motion
abnormality index (WMAi) (n = 41)
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milder reduction of LV mass and WMAi. Greater LV
mass resorption was associated with younger age.
Peak CK-MB, recovery and chronic scar size
Before the era of acute coronary reperfusion, it was
shown that the peak value of serially sampled CK-MB
after acute MI significantly correlates with scar size at
autopsy [16]. More recently, peak CK-MB has been
shown to correlate well with infarct size after reper-
fused MI [11, 17–19]. In these studies, patients usu-
ally had large MIs. Our finding that peak CK-MB has
a strong association with recovery phase and chronic
phase scar size after revascularized MI supports earl-
ier studies, and adds to current knowledge that this
association is valid also in smaller non-transmural
infarcts.
In this study, CMR missed small infarcts with peak
CK-MB ranging from 19 to 39 μg/L. This is in accord-
ance with a previous study by Choi et al. [20], in which
patients with peak CK-MB less than 38 μg/L after the
first revascularized MI had no enhancement on CMR,
and a study by Hedström et al. [17] .
In our study, only 19% of patients had a transmural
MI by definition, although 81% of patients presented
with STEMI. However, this is similar to a recent
study by Rodriguez-Palomares JF et al. [21], in which
22% of STEMI patients treated with PCI had trans-
murality index more than 75% enhancement of wall
thickness in acute phase CMR 15 min after contrast
injection. Thus, due to early revascularization, most
of the infarcts in our study did not evolve to fully
transmural.
Infarct resorption
We found that after the first weeks recovery phase,
there still happens considerable proportional infarct
resorption of 26% in median before chronic infarct
phase. This is in accordance with studies by Pokorney
et al. [22], demonstrating 32% and 12% decrease in
infarct mass from 1 week to 4 months and 4 months
to 14 months, and by Lund et al. [23], demonstrating
26% infarct resorption between 5 days and 8 months,
after reperfused MI. As Pokorney et al., we showed
that proportional infarct resorption is independent of
initial infarct size.
Infarct size and LV dysfunction
EF and ESV have been established as strong predictors
of cardiac outcome after MI [24], while infarct size as
the best predictor of LV dysfunction [2, 7]. We found
that peak CK-MB is correlated with recovery and
chronic phase ESV, EF and WMAi after revascularized
MI, with similar correlations in non-transmural MIs
only. In a recent study of patients with large anterior
ST-elevation myocardial infarction (median peak CK-
MB 240 IU/L) treated with primary PCI, peak CK-MB
was associated with EF (r = − 0.56, p < 0.001) at 1 month
follow-up CMR [19]. In another study of patients with
large reperfused MI, all cardiac biomarkers CK-MB,
troponin T, and troponin I correlated with EF at 1
month follow-up single-photon emission computer
tomography [11]. Earlier, it has been presented that LV
remodeling rarely occurs with infarct size less than
18.5% of LV volume [8]. In a study by Lund et al. it was
shown that infarct size of 24% or more is an important
predictor of remodeling (20% increase in LV end-
diastolic diameter) between acute and chronic phase
[23]. Our patients had mainly non-transmural infarcts,
with a median peak CK-MB of 86 μg/L and scar size of
13% at 1 month CMR. Thus, we showed that also after
smaller non-transmural MIs, peak CK-MB, as well as
recovery and chronic scar size, correlate with chronic
global and local LV dysfuntion. Furthermore, the best
overall model to predict chronic EF in our whole study
group included peak CK-MB and recovery phase EF.
Few prospective data is available on the association
between infarct size and chronic local segmental wall
motion abnormalities after revascularized acute MI.
Our finding that peak CK-MB, recovery scar size, and
chronic scar size, all correlate strongly with chronic
WMAi (r ≥ 0.75, p < 0.001), and similarly in non-
transmural MIs only (r ≥ 0.73, p < 0.001), is in accord-
ance with a recent retrospective analysis of patients
with previous (> 6 months) MI, in which infarct size
correlated with WMAi but the association was more
significant in transmural compared to non-transmural
MIs [25] .
Large infarct size has been previously associated with
progressive LV remodeling [7]. In our study, neither
peak CK-MB nor scar size at recovery phase were associ-
ated with late remodeling between recovery and chronic
phases. This is probably due to fact that most of our pa-
tients had small to intermediate sized infarcts and that
the infarct related remodeling occurred primarily during
the first weeks recovery phase. Earlier, it has been sug-
gested that late remodeling would be triggered by factors
different from initial infarct size, such as progressive is-
chemia [4]. The only predictor of late remodeling in our
patients was age; younger half of patients having greater
LV mass resorption (median 9% vs. 1%, p = 0.007). Left
ventricular hypertrophy is an important compensatory
mechanism after MI, but prolonged progression of
cardiac hypertrophy leads to heart failure. It has been
presented that post-infarction LV remodeling is more
pronounced in elderly patients due to inability to cope
with increased myocardial stress [26], explaining the
association between aging heart and milder late LV mass
resorption in our study.
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Predictors of cardiac survival
In our patients, chronic WMAi was the only predictor
of MACEs in the long-term, while multiple vessel dis-
ease, late increase in EDV or WMAi, showed tendency
toward adverse prognosis. Predictors of long-term out-
come in our study may be more related to severity of
coronary artery disease than infarct size, since the me-
dian scar size was relatively small and most MACEs
were recurrent MIs. Earlier, both WMAi and scar size
have been shown to be independent predictors of
MACEs after large reperfused ST-elevation myocardial
infarction [27] .
Study limitations
The number of patients was limited. Infarct related
artery patency was not verified after baseline. Our
data included patients treated with different revascu-
larization strategies, such as thrombolysis, PCI or
CABG, and cannot be generalized to solely one of
these groups. Tamaki et al. have shown that acute
coronary reperfusion alters kinetics of CK-MB, result-
ing in greater and earlier CK-MB release in the serum
with equivalent infarct volume [28]. In our study,
some peak CK-MB values were measured before and
some after revascularization, which had influence on
peak values and possibly weakened correlations to LV
remodeling. Chronic phase CMR study was performed
in a median of 10 (8–16) months after hospital ad-
mission; thus the period between CMRs was varied.
We did not systematically evaluate the relation be-
tween troponins and remodeling, although troponins
are preferred markers in detection of acute MI ac-
cording to current guidelines [10], while CK-MB is
the best alternative. Follow-up data was collected
post-hoc and the number of MACEs was limited. We
did not assess microvascular obstruction or myocar-
dial salvage area which both omit prognostic value
after MI [29].
Conclusions
Peak CK-MB has a strong association with chronic scar
size and WMAi after revascularized non-transmural MI.
Considerable infarct resorption happens after the first-
month recovery phase, independently of infarct size, and
LV mass resorption is related to age, being more com-
mon in younger patients. At the era of increasing im-
aging modalities and costs, peak CK-MB provides robust
estimation of infarct size, predicting chronic local and
global LV function after revascularized MI.
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